Mundipharma empowers global healthcare access with acquisition of Rezafungin rights

In a recent announcement, Mundipharma, a leading global pharmaceutical company, has announced its acquisition of all assets and rights related to
rezafungin from Cidara Therapeutics.

This solidified Mundipharma’s dedication to managing infectious diseases and specialty care therapeutic areas, especially invasisve candidiasis which over
the 15 years has seen no new therapeutic developments underscoring for alternative options.

The FDA and MHRA approved rezafungin is a groundbreaking once-weekly echinocandin antifungal drug specifically designed for the treatment of invasive candidiasis
in adults.

While Mundipharma will oversee global commercialization efforts, Melinta Therapeutics will retain commercialization rights for rezafungin in the United States.

Moreover, the acquisition empowers the pharmaceutical company with global ownership of rezafungin, encompassing its ongoing development and distribution.